Inquiry Basket
CAS No.: 1938099-52-5
Cat No.: BADC-01491
4.5 
MP-PEG8-VA-PABC is a biomedical product used for targeted drug delivery in cancer treatment. With its polyethylene glycol (PEG) and maleimide functional groups, it efficiently conjugates to antibodies or therapeutic agents, enabling precise and controlled release at the tumor site. It shows potential in treating various types of cancers, including breast, lung, and prostate cancer.
Structure of 1938099-52-5
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
MP-PEG8-VA-PABC, a multifunctional linker crucial in the advancement of cutting-edge drug delivery systems, boasts a myriad of applications.
Targeted Drug Delivery: MP-PEG8-VA-PABC plays a pivotal role in crafting targeted drug delivery vehicles that ferry therapeutics directly to ailing cells or tissues. By coupling this linker with drugs and targeting moieties, researchers adeptly enhance drug uptake by specific cells, especially cancer cells. This tailored strategy curtails off-target effects, amplifying the potency of treatments.
Prodrug Design: MP-PEG8-VA-PABC emerges as a crucial spacer and triggerable linker, governing the union between the active pharmaceutical ingredient (API) and the aiming entity. The strategic use of this linker permits controlled release of the API upon reaching the designated site, ensuring drug activation solely at the requisite location.
Bioconjugation: Within the domain of bioconjugation processes, MP-PEG8-VA-PABC acts as a linchpin, bridging biologically active molecules like peptides or antibodies to polymers or diverse compounds. This linkage begets bioconjugates endowed with heightened stability, solubility, and bioavailability, pivotal in crafting diagnostic tools and avant-garde therapeutic agents.
Complex Drug Formulation: Pioneering complex drug formulations, MP-PEG8-VA-PABC orchestrates the union of multiple therapeutic agents within a unified delivery framework. This innovation enables the concurrent dispensation of diverse drugs with synergistic impacts against ailments such as cancer and infectious diseases. By harnessing such formulations, researchers steer toward enhanced therapeutic efficacy and surmounting drug resistance.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01451 | MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT | 2378428-19-2 | |
| BADC-01517 | MP-PEG4-VK(Boc)G-OSu | 2378428-21-6 |
MP-PEG8-VA-PABC
Required fields are marked with *
MP-PEG8-VA-PABC
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
